Table 1.
Nanobodies in Cancer Clinical Trial.
| Product name | Disease | Target | Phase | Clinical trial identifier | References |
|---|---|---|---|---|---|
| ALX-0651 | Non-Hodgkin’s lymphoma and multiple myeloma | CXCR4 | I | NCT01374503 | 53 |
| DR5Nb1 | Colon and pancreatic cancers | DR5 | I | 32 | |
| [131I]-SGMIB anti-HER2 VHH1 | Breast cancer | HER2 | I | NCT02683083 | 54 |
| TAS266 | Solid tumors | DR5 | I | NCT01529307 | 55 |
| 68GaNOTA-Anti-HER2 VHH1 | Breast cancer | HER2 | I | 56 | |
| 99mTc-NM-02 | Breast cancer | HER2 | I | NCT04040686 | |
| KN035 | Solid tumors | PD-L1 | I | NCT03248843 | 57 |
| KN044 | Advanced solid tumors | CTLA-4 | I | NCT04126590 | |
| CD19/CD20 bispecific CAR T cells | B-cell lymphoma | CD19/CD20 | I | NCT03881761 | 58 |
| BCMA CAR T cells | Myeloma | BCMA | I | NCT03664661 | 59 |
| 68 GaNOTA-Anti-MMR VHH2 | Malignant solid tumor | MMR | I/IIa | NCT04168528 | 60 |
Abbreviations: BCMA, B-cell maturation antigen; CD19/CD20, cluster of differentiation 19/20; CTLA-4, cytotoxic T lymphocyte antigen-4; CXCR4, chemokine receptor type 4; DR5, death receptor-5; MMR, macrophage mannose receptor.